BIOGEN INC. - COMMON STOCK

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

06 Feb 2026 09:46:52 By NetDania Notify

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

12 Jan 2026 11:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

09 Jan 2026 09:47:21 By NetDania Notify

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

08 Jan 2026 09:46:19 By NetDania Notify

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

07 Jan 2026 10:14:30 By NetDania Notify

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

05 Jan 2026 20:00:00 By Nasdaq GlobeNewswire

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

22 Dec 2025 11:20:00 By Nasdaq GlobeNewswire

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List

08 Dec 2025 18:30:00 By Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

05 Dec 2025 09:00:00 By Nasdaq GlobeNewswire

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

03 Dec 2025 18:10:00 By Nasdaq GlobeNewswire

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

02 Dec 2025 16:40:00 By Nasdaq GlobeNewswire

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

01 Dec 2025 07:30:00 By Nasdaq GlobeNewswire

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

27 Nov 2025 19:30:00 By Nasdaq GlobeNewswire

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

25 Nov 2025 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

24 Nov 2025 09:45:02 By NetDania Notify

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

24 Nov 2025 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

21 Nov 2025 10:07:15 By NetDania Notify

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

20 Nov 2025 10:47:02 By NetDania Notify

Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference

20 Nov 2025 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

18 Nov 2025 12:26:07 By NetDania Notify